CADL logo

CADL Candel Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$5.04
-0.09 (-1.75%)

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials f…

Market Cap: $395.37Mwww.candeltx.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
58
3 mentions
—
60d
56
4 mentions
—
90d
50
8 mentions
—
news: 8

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 0Sell 0Strong Sell 0
Avg price target$22.33+343.1%
Low $19Median $23High $25
Current Consensus

Revenue

$0.00-100.00%
$0.00$10.3K$20.7K$31.0K
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-0.42
$-0.43–$-0.40
2 analysts
FY2026
$-1.29
$-1.32–$-1.25
4 analysts
FY2027
$-1.51
$-2.05–$-1.23
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Paul-Peter Tak
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
-0.47
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
0.52
www.candeltx.com